ArticleCancers2025

Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study.

Carlo Signorelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.